bADA has been shown to be an irreversible cysteine protease inhibitor that contains aziridine-2,3-dicarboxylic acid as a reactive agent. The compound has been reported to be active against the plasmodial protease falcipain 2 and against the lysosomal cysteine protease cathepsin L. In vivo experiments, performed on malaria parasite invaded red blood cells, have noted bADA to act on parasite proteins in the host cell cytosol and digestive vacuole. Inhibition of cysteine protease has been demonstrated to block apoptosis of the host cell membrane. Other studies suggest that bADA may be used to detect B. henselae infection.
1. Egland, P.G., et al. 1995. J. Bacteriol. 177: 6545-6551. PMID: 7592432
2. Gelhaus, C., et al. 2004. Biol. Chem. 385: 435-438. PMID: 15196005
3. Gelhaus, C., et al. 2005. Biol. Chem. 386: 499-502. PMID: 15927894
4. Wagner, C.L., et al. 2008. Int. J. Med. Microbiol. 298: 579-590. PMID: 18501673